TMEM194 Inhibitors
Chemical inhibitors of TMEM194 function by disrupting the cell cycle regulation and kinase-mediated signaling pathways. Alsterpaullone, a cyclin-dependent kinase (CDK) inhibitor, can inhibit TMEM194 by impeding the cell cycle processes with which TMEM194 is associated, leading to interruption of its role in cell proliferation. Similarly, Roscovitine and Paullone target CDKs, preventing the phosphorylation events necessary for cell cycle control, which can lead to functional inhibition of TMEM194 if its activity is contingent upon such events. Indirubin-3'-monoxime, another kinase inhibitor, can disrupt TMEM194 function by preventing phosphorylation by not only CDKs but also glycogen synthase kinase 3-beta (GSK-3β), potentially decreasing TMEM194 activity.
Further, Purvalanol A, a potent inhibitor of several CDKs, can prevent phosphorylation of TMEM194 substrates, leading to functional inhibition if TMEM194 activity depends on these phosphorylation events. PD0332991 (Palbociclib) is selective for CDK4 and CDK6 and can inhibit TMEM194 by halting cell cycle progression, which may be essential for TMEM194's function. Flavopiridol, by inhibiting multiple CDKs, can impede the phosphorylation state of proteins with which TMEM194 may interact or regulate. Olomoucine, Dinaciclib, Milciclib, AZD5438, and RGB-286638, all of which are CDK inhibitors, can lead to functional inhibition of TMEM194 by interfering with the kinase-dependent processes and cell cycle progression that are essential for the role of TMEM194 within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone, a known inhibitor of cyclin-dependent kinases (CDKs), can inhibit TMEM194 by disrupting the cell cycle regulation processes that TMEM194 is associated with, thereby leading to the interruption of its role in cell proliferation and potentially other cell cycle-dependent functions. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine selectively inhibits CDKs, which are crucial for cell cycle progression. By inhibiting these kinases, the assembly and function of multiprotein complexes that include TMEM194 could be impaired, leading to functional inhibition of TMEM194 as it may rely on proper cell cycle progression for its activity. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
Indirubin-3'-monoxime is known to inhibit CDKs and glycogen synthase kinase 3-beta (GSK-3β). Since TMEM194 function might be regulated through phosphorylation by these kinases, inhibition by indirubin-3'-monoxime could lead to a decrease in TMEM194's functional activity by preventing necessary phosphorylation events. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is a potent inhibitor of CDKs, particularly CDK1, CDK2, and CDK5. By inhibiting these kinases, Purvalanol A can inhibit the phosphorylation of TMEM194 substrates, leading to functional inhibition of TMEM194 if its activity is dependent on the phosphorylation of these substrates. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
PD0332991, also known as Palbociclib, is a selective inhibitor of CDK4 and CDK6. TMEM194, involved in cell cycle-related processes, could be functionally inhibited by PD0332991 through the inhibition of cell cycle progression, which might be a prerequisite for the functional activity of TMEM194. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits several CDKs, which could lead to the functional inhibition of TMEM194 by impeding cell cycle progression and the phosphorylation state of proteins that TMEM194 may interact with or regulate. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective inhibitor of CDKs. By inhibiting the CDKs, Olomoucine can interfere with the phosphorylation events necessary for cell cycle progression, which TMEM194 is potentially involved in. This could result in the functional inhibition of TMEM194 due to a failure to properly progress through the cell cycle. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib is a potent CDK inhibitor affecting multiple CDKs. Inhibition of these kinases can lead to the functional inhibition of TMEM194, as it may be implicated in cell cycle regulation and other kinase-dependent processes. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib, known to inhibit multiple CDKs, can lead to the functional inhibition of TMEM194 by disrupting cell cycle-dependent processes and kinase-mediated signaling pathways that TMEM194 is part of, leading to its functional inhibition. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 is an inhibitor of CDK1, CDK2, and CDK9. The inhibition of these kinases can lead to the functional inhibition of TMEM194 by preventing the phosphorylation of associated proteins and disrupting cell cycle progression, which could be essential for TMEM194's functional activity. | ||||||